obesity-995x60.png
FEATURED ARTICLES
To Pick The Right Medical LLM, First Assess Your Readiness
Learn how to evaluate medical LLMs for clinical trials by weighing readiness, risk, validation, integration, hidden costs, and supplier controls.
-
![clinical-trial-ethics-GettyImages-2186759526]( "How Phase I Trial Ethics Are Changing For Sponsors")
How Phase I Trial Ethics Are Changing For SponsorsAs early efficacy becomes possible in Phase I studies, hope for benefit must be weighed against limited knowledge, reshaping consent language, risk-benefit review, and protocol design for sponsors and IRBs.
-
![solution, teamwork-GettyImages-2198585740]( "Your Company Needs Compliance Expertise — But When And From Whom?")
Your Company Needs Compliance Expertise — But When And From Whom?When should a biotech formalize compliance? Learn how risk, funding, clinical activity, and commercialization shape the right expertise and structure.
-
![Feasibility_Panelists_450x300]( "Can We Make Feasibility More Realistic?")
Can We Make Feasibility More Realistic?Drawn from a Clinical Leader Live webinar, this article explores how sponsors can make clinical trial feasibility and enrollment forecasts more realistic by questioning data sources, examining patient and site burdens, challenging protocol assumptions, and looking beyond seemingly convincing answers from historical data and AI.
SERVICES AND PRODUCTS
Explore the breadth of Altasciences’ expertise in clinical pharmacology studies, supporting regulatory submissions across a diverse range of therapeutic areas.
Managing clinical trial disclosure can be challenging with the ever-evolving regulatory landscape, and varying requirements across different jurisdictions and regulatory bodies. New and updated regulations need to be continuously monitored and assessed for potential impact on an organization, processes and overall strategy.
Ypsomed accelerates clinical progress by reducing barriers across clinical development, enabling earlier study readiness, greater visibility and more informed decisions.
Explore validated pain models and integrated early-phase services designed to characterize dose response, evaluate safety and efficacy, and support informed decisions in analgesic development.
DECODE, the Digital Endpoint Collaboration for Outcomes Development, is Ametris’ pre-competitive collaboration framework designed to help address shared clinical measurement challenges across the life sciences industry. In regulatory contexts where evidence expectations are high, digital measures must be meaningful to patients, scientifically valid, operationally feasible, and aligned with regulatory expectations. By supporting the development and validation of fit-for-purpose, patient-centered digital measures, DECODE helps transform real-world data into validated clinical evidence across clinical research programs.